clinical trial · NCT05298033
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
University of Colorado, Denver·phase2·completed·n = 32
VitiligoCrisaborole 2 % Topical OintmentPF-07038124 0.01% topical ointmentNBUVB phototherapySham phototherapyVehicle
brief summary
This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions. This is a double-blind, randomized controlled trial (RCT) with six study arms. The goal is for 64 participants to be recruited and complete the study.
started
Sep 7, 2022
primary completion
Apr 30, 2024
completion
Apr 30, 2024
last updated
Jun 12, 2024
official title
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo: A Phase 2A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol